Physician profile
Michael Warren
NPI 1154388940
$591.57
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $17.27 · 2022: $107 · 2023: $53.63 · 2024: $96.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $96.41 | 2024 | Tremfya |
| Genentech USA, INC. | $83.48 | 2019 | |
| Sun Pharmaceutical Industries INC. | $67.84 | 2019-2022 | |
| Celgene Corporation | $53.60 | 2019 | |
| Lilly USA, LLC | $50.25 | 2019 | |
| Pfizer INC. | $42.87 | 2019-2022 | |
| Janssen Biotech, INC. | $42.54 | 2019-2023 | Simponi, Simponi Aria, Remicade |
| Amgen INC. | $39.44 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.25 | 2019-2020 | |
| Abbvie INC. | $28.54 | 2019 | |
| Incyte Corporation | $23.63 | 2023 | Opzelura |
| Ucb, INC. | $18.46 | 2019 | |
| Mayne Pharma Commercial LLC | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.